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Abstract
The widespread use of next generation sequencing for clinical testing is detecting an escalating
number of variants in noncoding regions of the genome. The clinical significance of the majority
of these variants is currently unknown, which presents a significant clinical challenge. We have
screened over 6,000 early-onset and/or familial breast cancer (BC) cases collected by the ENIGMA
consortium for sequence variants in the 5′ noncoding regions of BC susceptibility genes BRCA1
and BRCA2, and identified 141 rare variants with global minor allele frequency < 0.01, 76 of which
have not been reported previously. Bioinformatic analysis identified a set of 21 variants most likely
to impact transcriptional regulation, and luciferase reporter assays detected altered promoter
activity for four of these variants. Electrophoretic mobility shift assays demonstrated that three of
these altered the binding of proteins to the respective BRCA1 or BRCA2 promoter regions, including NFYA binding to BRCA1:c.-287C>T and PAX5 binding to BRCA2:c.-296C>T. Clinical classification of variants affecting promoter activity, using existing prediction models, found no evidence to
suggest that these variants confer a high risk of disease. Further studies are required to determine
if such variation may be associated with a moderate or low risk of BC.
KEYWORDS

breast cancer, BRCA1, BRCA2, promoter, transcription, variants of unknown clinical significance
(VUS)
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1

INTRODUCTION

variants to clinical testing of Mendelian disease genes, and so the vast
majority of such variants are deemed of uncertain clinical significance.

Genetic susceptibility to breast cancer (BC) is complex. Multiple
germline variants have been identified over the past 25 years that are
broadly categorized as high, moderate, and low risk. High-risk variants
are generally rare, have a major deleterious effect on gene function,
are sufficient to confer a high risk of disease, and are highly penetrant
within a family. Nonsense, splicing, large deletions, and some missense
changes in BRCA1 and BRCA2 fall into this category (reviewed in Walsh
et al., 2006). There is also evidence that some alleles confer a moderate risk of cancer. These can include hypomorphic variants in known
“high-risk” cancer syndrome genes (Shimelis et al., 2017; Spurdle et al.,
2012), or clear loss-of-function alleles in other genes such as CHEK2,
PALB2, and ATM (Couch et al., 2017). Low-risk variants, largely identified by genome-wide association studies, are usually common and
cause subtle functional effects, such as small but significant changes
in gene expression due to altered activity of proximal and distal
regulatory elements (reviewed in Bogdanova, Helbig, & Dork, 2013;
Ghoussaini, Pharoah, & Easton, 2013; Skol, Sasaki, & Onel, 2016).
Evidence suggests that combinations of low, moderate, and high-risk
variants could confer a clinically significant risk of disease (Ding et al.,
2012; Kuchenbaecker et al., 2017; Sawyer et al., 2012). Identification
and evaluation of all such variants is therefore crucial for accurately
predicting BC risk.
Use of next generation sequence analysis for germline clinical testing of cancer cases is identifying an increasing number of variants in
noncoding regions of cancer susceptibility genes, including promoters, untranslated regions (UTRs), and introns. There are currently no
firm recommendations for assessing the relevance of noncoding region

This adds to the clinical challenge presented by variants of uncertain
significance, namely that they complicate test reporting and genetic
counseling, limit patient eligibility for intensive surveillance and genetargeted therapies, and prevent gene testing and guided management
of relatives (reviewed in Amendola et al., 2015; Eccles et al., 2013; Plon
et al., 2011). It is therefore essential that the functional and clinical significance of variants mapping to noncoding regions of the genome is
determined.
Gene expression is controlled at many levels with key regulatory
elements being housed in noncoding regions of the genome, such as
gene promoters, introns, long-range elements, and 5′ and 3′ UTRs.
The BRCA1 gene is regulated at the transcriptional and posttranscriptional levels, with functional proximal and distal regulatory elements
being described in the promoter, introns, and UTRs, by us and others
(Brewster et al., 2012; Brown et al., 2002; Santana dos Santos et al.,
2017; Saunus et al., 2008; Tan-Wong, French, Proudfoot, & Brown,
2008; Wardrop, Brown, & kConFab, 2005; Wiedemeyer, Beach, &
Karlan, 2014). Although less studied, the BRCA2 promoter has also
been mapped and characterized (reviewed in Wiedemeyer et al., 2014).
Common and rare variations in regulatory elements upstream of
genes have been shown to alter gene expression and be associated with disease risk (reviewed in Betts, French, Brown, & Edwards,
2013; Diederichs et al., 2016; Millot et al., 2012). We and others
have described germline cancer-associated variants in the regulatory regions, including large deletions in the BRCA1 promoter (Brown
et al., 2002), and single nucleotide variants in the promoter and/or
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5′ UTR of BRCA1 and BRCA2 (Evans et al., 2018; Santana dos Santos et al., 2017), MLH1 promoter (Hitchins et al., 2011), POLG promoter (Popanda et al., 2013), PTEN promoter (Heikkinen et al., 2011),
TERT promoter (Horn et al., 2013), KLHDC7A and PIDD1 promoters
(Michailidou et al., 2017), BRCA1 3′ UTR (Brewster et al., 2012), and
BC-associated Single Nucleotide Polymorphisms (SNPs) in long-range
enhancers of CCND1 (French et al., 2013).
Cancer risk-associated variants within regulatory regions are anticipated to mediate an effect on trans-acting regulatory factors (e.g.,
transcription factors [TFs] and miRNAs), by disrupting binding of regulatory factors and interactions between regulatory elements, such
as promoter–enhancer interactions. For example, a variant in a Cyclin
D1 transcriptional enhancer has been associated with altered binding
of the ELK4 TF (French et al., 2013) and a variant within the BRCA1
3′ UTR has been shown to introduce a functional mir-103 binding site
(Brewster et al., 2012). In addition, a dominantly inherited 5′ UTR
BRCA1 variant was recently shown to be associated with BRCA1 promoter hypermethylation, which is known to impact TF binding, and
associated allelic loss of BRCA1 expression in two families affected by
breast and ovarian cancers (Evans et al., 2018).
In this paper, we describe 141 germline variants in the BRCA1 and
BRCA2 promoter, identified by members of the ENIGMA consortium in
early onset or familial BC patients with no known pathogenic variants
in the coding region of these genes. Using a combination of bioinformatic and experimental analyses, we have prioritized and analyzed a

F I G U R E 1 Overview of study design. Outline of the workflow of
variant collection, prioritization and analysis

subset of variants that are most likely to affect the regulation of BRCA1
and BRCA2 and thus have the most potential to contribute to BC risk.
TF binding site affinity changes resulting from these variants were subsequently analyzed by information theory (IT)-based analyses. In parallel, we have assessed if these variants exhibited the features expected
for a high-risk pathogenic BRCA1 or BRCA2 variant, on the basis of
available clinical and population data.

and young age of BC diagnosis. Female patients who did not carry a
pathogenic variant in BRCA1 or BRCA2 coding regions or splice junctions were selected for testing of variation in the BRCA1 and BRCA2 5′
regions. The controls were as follows: 661 healthy female individuals
recruited through the Immunohematology and Transfusion Medicine
Service of INT and Associazione Volontari Italiani Sangue (AVIS) of

2
2.1

MATERIALS AND METHODS
Study design

An overview of the study design is shown in Figure 1. Collection of vari-

Milan; 312 healthy females above 60 years of age and with no malignancy in the first filial generation recruited through First Faculty of
Medicine, Charles University in Prague (Lhota et al., 2016; Soukupova,
Zemankova, Kleiblova, Janatova, & Kleibl, 2016); and 130 healthy
females without cancer diagnosis recruited in Santiago de Compostela.

ants at all sites enabled an initial catalogue of variants from which variants were prioritized for functional analysis. Additional screening was
carried out at three sites, Maastricht (M), Santiago (S), and Prague (Pr),
that included additional patients (M, S, and Pr) and controls (Pr) that
expanded the list of variants (Pr), the number of patients (M, S, and Pr),
and included control subjects (Pr).

2.3

Identification of variants

Regions containing the BRCA1 and BRCA2 promoter and 5′ UTR
were sequenced using a range of standard DNA sequencing technologies, and bioinformatic filtering pipelines. Variants mapping to the
2,400 bp region (hg19; chr17:41,278,514 – 41,276,114) of BRCA1

2.2

Clinical and control samples

and the 2,000 bp region (hg19; chr13: 32,888,597-32,890,597) of
BRCA2 were considered for further analysis. The identified vari-

Clinical and genetic data were collected and analyzed in accordance

ants in BRCA1 and BRCA2 5′ noncoding regions are numbered

with local human ethics guidelines of the institutions contributing to

whereby the first translated nucleotide of the translation initiation

this study. All participating individuals provided informed consent for

codon is +1 (https://varnomen.hgvs.org/) using the Mutalyzer website

their data to be used for research purposes. An overview of the sam-

(https://mutalyzer.nl/). BRCA1 is described using NC_000017.10 (hg19

ples analyzed is shown in Table 1. Clinical samples were collected

genomic sequence) and NM_007294.3 (transcript). BRCA2 is described

from nine European sites and were originally selected for BRCA1 and

using NC_000013.10 (hg19 genomic sequence) and NM_000059.3

BRCA2 testing using ascertainment criteria that included family history

(transcript).
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TA B L E 1

Samples used in this study

Location

Institution

Samples

Gene region

Paris

Institut Curie, Saint Cloud

686 cases

BRCA1 5′ region, BRCA2 5′ region

Milan

IFOM, Fondazione Instituto FIRC di Oncologia
Molecolare

772 cases
661 controls

BRCA1 5′ region

Pisa

Department of Translational Research and New
Technologies in Medicine, University of Pisa

80 cases

BRCA1 5′ region, BRCA2 5′ region

Santiago de
Compostela

Fundación Pública Galega de Medicina
Xenómica-SERGAS, Grupo de Medicina
Xenómica-USC, CIBERER, IDIS

270 cases
130 controls

BRCA1 5′ region, BRCA2 5′ region

Copenhagen

Center for Genomic Medicine

1157 cases

BRCA1 5′ region, BRCA2 5′ region

Ghent

Center for Medical Genetics, Ghent University
Hospital

357 cases

BRCA1 5′ region, BRCA2 5′ region

Barcelona

Vall d'Hebron Institute of Oncology

192 cases

BRCA1 5′ region, BRCA2 5′ region

Prague

CZECANCA – CZEch CAncer panel for Clinical
Aplication, Institute of Biochemistry and
Experimental Oncology

2961 cases
312 controls

BRCA1 5′ region, BRCA2 5′ region

Maastricht

Department of Clinical Genetics, Maastricht
University Medical Centre

900 cases

BRCA2 5′ region

2.4

Bioinformatic analysis of variants

pCR-Blunt vector (Thermo Fisher, Waltham, MA). Site-directed muta-

As an initial screen, each variant submitted for study was assessed
for population frequency using intersection of the variants with
dbSNP (version 138 or 150, as the study progressed) within the
UCSC Genome browser and Variant Effect Predictor at ENSEMBL
(https://www.ensembl.org/info/docs/tools/vep/index.html).

Variants

with a global minor allele frequency (MAF) of < 0.01 were included in
subsequent bioinformatic analyses. Further details of bioinformatics
analyses to map active regulatory elements and prioritize variants for
functional assays are contained in Supporting Information Methods.
Variants were considered to be high priority for experimental analysis
if they contained all of the following features: (1) resided in DNaseI or
formaldehyde-assisted isolation of regulatory elements (FAIRE) peaks,
(2) coincided with high scores for DNaseI (Base Overlap Signal > 40)
or FAIRE (Base Overlap Signal > 10) in a breast cell line, (3) resided
in a region of breast cell specific TF binding, (4) overlapped with a
TF consensus motif, and (5) were within an evolutionarily conserved
element with a high Phastcons score (>0.75). Medium priority variants
lacked one or two of these features, whereas low priority variants had
only one or none of these features.

2.4.1

genesis was used to introduce variants using the primers listed in
Supporting Information Table S1. Plasmids were purified using the
QIAprep miniprep kit (Qiagen, Hilden, Germany) as per the manufacturer's instructions. Plasmid preparations were validated using restriction digest and DNA sequencing and inserts were shuttled into pGL3Basic luciferase reporter vector (Promega, Madison, WI). All plasmids
for transfection were analyzed for DNA conformation on a 1% w/v
agarose gel and only plasmids possessing a supercoiled conformation
were used for transfections. Transfection details are described in Supporting Information Methods.
The luciferase-based reporter assay was performed as described
previously (Brewster et al., 2012). Positive controls were B1-Ets,
BRCA1:c.-330_-329delinsTT, that decreases BRCA1 promoter activity in MCF7 cells (Atlas, Stramwasser, Whiskin, & Mueller, 2000)
and B2-Ets (E2Fmut1: BRCA2:c.-282_-281delinsAA), that has been
shown to decrease BRCA2 promoter activity in MCF7 cells (Davis,
Miron, Andersen, Iglehart, & Marks, 1999). Statistical analyses were
performed in GraphPad Prism using one-way analysis of variance
followed by Tukey's post hoc test and values P < 0.05 were deemed
statistically significant.

In silico TF binding analysis

All rare variants were analyzed in silico using an IT-based method

2.5.2

Electrophoretic mobility shift assays

(Caminsky et al., 2016; Mucaki et al., 2016) and a modified version

Nuclear proteins were extracted as described in Supporting Infor-

of the Shannon pipeline utilizing TF information models built from

mation Methods and electrophoretic mobility shift assays (EMSAs)

ENCODE ChIP-seq datasets (Lu, Mucaki, & Rogan, 2017) to assess

were carried out using a Pierce LightShift Chemiluminescent EMSA

potential effects of variants on TF binding. Details of analyses are

Kit (Thermo Fisher, Waltham, MA) with modifications described in

contained in Supporting Information Methods.

Supporting Information Methods. For competition and supershift
studies, nuclear extracts were initially incubated with unlabeled

2.5

Experimental analysis of variants

double-stranded (ds) competitor probes or antibodies in binding
buffer before addition of the biotinylated probe and incubation at

2.5.1

Promoter reporter assays

room temperature. Positive controls for BRCA1 and BRCA2 DNA

The 499 bp BRCA1 (chr17:41,277,787-41,277,289) and 750 bp BRCA2

binding were sequences surrounding the B1-Ets and B2-Ets mutations

(chr13:32,889,230-32,889,979) promoter regions were cloned into

described above.
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2.6 Qualitative and quantitative classification
of variants

WT construct in the MCF7 cell line. For BRCA2, one of the 12 variants,
BRCA2:c.-296T, decreased BRCA2 promoter activity relative to the WT
construct in the MCF7 cell line (Figure 3c and 3d).

Variants were classified according to the ENIGMA classification criteria for variation in BRCA1 and BRCA2 (https://enigmaconsortium.org/)
to determine whether any of the prioritized variants were associated
with a high risk of disease. See Supporting Information Methods for
further details.

3.3 In silico analyses of BRCA1 and BRCA2 5′ variants
predict alterations in TF binding
BRCA1 and BRCA2 promoters are regulated by a complex array of
DNA-binding proteins and transcriptional coactivators and core-

3

pressors (reviewed in McCoy, Mueller, & Roskelley, 2003; Mueller

RESULTS

& Roskelley, 2003; Wiedemeyer et al., 2014). In silico analysis was
carried out to examine whether the BRCA1 and BRCA2 promoter

3.1 Identification and prioritization of sequence
variants in BRCA1 and BRCA2 5´ noncoding regions
The 5′

variants shown to alter luciferase activity (see above) are likely to
affect binding of trans-acting protein factors in breast cells.

noncoding regions of BRCA1 and BRCA2 in early onset or famil-

Interrogation of ENCODE ChIP-seq datasets derived from breast

ial BC patients with no known BRCA1 or BRCA2 germline pathogenic

cell lines show that, although the number of datasets is limited, TFs

variant were sequenced at nine different sites as part of an approved

bind to regions encompassing the prioritized variants (Figure 2 and

5′

Supporting Information Figure S1). ENCODE ChIP-seq data from

region, 6,475 patients were sequenced at eight different sites along

other cell lines indicate that some variants are located within con-

ENIGMA (https://enigmaconsortium.org/) project. For the BRCA1
with 1,103 controls. For the BRCA2

5′

region, 6,603 patients were

sequenced at eight different sites as well as 442 controls.
After excluding variants with global MAF > 0.01 at time of variant identification, a total of 141 unique single nucleotide variants

sensus motifs for specific TFs associated with these regions (Tables 2
and 3; Supporting Information Figure S1). BRCA1:c.-287C>T overlaps
with the consensus binding motif for CCAAT Box binding factors and
BRCA2:c.-296C>T is located within the consensus motif for PAX5.

and short insertions/deletions were identified, 81 in BRCA1 and 60

IT analysis of the prioritized variants showed that the binding

in BRCA2 (Supporting Information Tables S2 and S3). Theses variants

strengths of several TFs are predicted to be altered by the BRCA1

have been submitted to the LOVD databases, www.lovd.nl/BRCA1 and

and BRCA2 variants (Table 4 and Supporting Information Table S4). All

www.lovd.nl/BRCA2. To evaluate the potential of these rare variants to

of the variants that altered promoter activity were predicted to have

impact gene regulation, we initially undertook a comprehensive bioin-

consequences on TF binding. BRCA1:c.-287C>T and BRCA2:c.-296C>T

formatic analysis. Promoter regions of BRCA1 and BRCA2 were defined

are predicted to disrupt binding of CCAAT Box binding factors and

by bioinformatic predictors including chromatin marks (Figure 2).

PAX5, respectively. BRCA1:c.-315del is predicted to disrupt the binding

These regions show the characteristic histone H3 epigenetic marks,

of TCF7L2 but creates a POU2F2 (also known as Oct-2) binding site.

including H3K4me3, H3K27ac, and H3K9ac, as well as occupancy by

BRCA1:c.-192T>C is predicted to strengthen a RFX5 site and creates

multiple TFs. Of the variants identified in cases only, 22 BRCA1 and 23

an ETS1 site.

BRCA2 variants resided within the minimal promoter regions.
To predict the potential impact of variants on promoter activity, we
prioritized variants using breast cell specific data for chromatin accessibility and TF occupancy along with evolutionary conservation. Due

3.4 5′ variants in BRCA1 and BRCA2 alter
protein–DNA interactions in EMSA analyses

to the limited breast cell specific TF ChIP-seq data, we also included

To examine potential alterations in the binding of nuclear proteins from

ENCODE TF ChIP-seq and TF consensus motif data from all cell lines.

breast cells by the BRCA1 and BRCA2 promoter variants that altered

A total of nine BRCA1 and 12 BRCA2 variants were selected for further

luciferase activity, we carried out EMSA analysis. For BRCA1, two of

functional analysis (Figure 2; Tables 2 and 3).

three analyzed variants, c.-315del and c.-287C>T, displayed allelespecific protein binding (Figure 4). For probes containing the region

3.2 BRCA1 and BRCA2 promoter activity is altered
by 5′ noncoding sequence variants

surrounding the BRCA1:c.-315del variant, changing the WT sequence

To examine the potential effect of the 21 prioritized BRCA1 and BRCA2

surrounding the BRCA1:c.-287C˃T variant, introduction of the variant

5′ noncoding variants on regulatory activity, promoter activity was

sequence resulted in almost complete loss of protein binding to the

measured using luciferase assays in MCF7 and MDA-MB-468 BC cell

probe (Figure 4a).

to the variant sequence resulted in the enhanced binding of a slower
migrating band (Figure 4a and 4b). For probes containing the region

lines. Two of the nine prioritized BRCA1 variants decreased BRCA1

To determine if the DNA-protein interactions were specific, com-

promoter activity relative to the wild-type (WT) construct (Figure 3a

petition experiments were performed. In the case of BRCA1:c.-315del,

and 3b). BRCA1:c.-315del significantly decreased the BRCA1 pro-

all bands were competed by both the WT and the variant containing

moter luciferase activity in both cell lines, whereas BRCA1:c.-192C

probes in two cell lines (Figure 5a and 5b). For BRCA1:c.-287C>T,

decreased luciferase activity in the MCF7 cell line. Furthermore, one

only the WT probe was able to compete for binding (Figure 5c). The

variant, BRCA1:c.-287T, displayed increased activity relative to the

nonspecific probe from an unrelated region of the BRCA1 promoter
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Variants identified in the 5′ regions of BRCA1 and BRCA2 map to predicted regulatory elements. Snapshots of the UCSC genome
browser showing regions of BRCA1 (a) and BRCA2 (b) analyzed by targeted sequencing with available ENCODE regulatory marks derived from
MCF7 cells. Chromatin segregation states from regulatory region annotation are shown (MCF7 states). The BRCA1 and BRCA2 genomic regions
used for functional analyses are highlighted in grey. Prioritized variants within these regions are indicated
FIGURE 2

TA B L E 2

BRCA1 prioritized variants

Gene

hg19 position
(chr17)

Variant
namea

rsID

BRCA1

g.41277676A>T

c.-408T>A

Novel

CEBPB

High/medium

BRCA1

g.41277648C>T

c.-380G>A

Novel

RXRA

High/medium

BRCA1

g.41277646G>T

c.-378C>A

rs186775935

0.00040

RXRA

High/medium

BRCA1

g.41277583del

c.-315del

rs901029407

0.00003

ATF1,2,3, CREB1c

Medium

BRCA1

g.41277555G>A

c.-287C>T

Novel

BRCA1

g.41277541C>T

c.-273G>A

rs112960339

0.00499

Medium

BRCA1

g.41277532A>C

c.-264T>G

rs904148166

0.00003

Medium

BRCA1

g.41277488G>T

c.-220C>A

Novel

BRCA1

g.41277460A>G

c.-192T>C

rs113323025

TF, transcription factors.
a
Based on NM_007294.3.
b
Overlap with TF motif in ENCODE TF-ChIP datasets from all cells.
c
Variant overlaps this motif, but the deletion does not alter the motif sequence.

Global MAF
in dbSNP

TF motif
(ENCODE)b

NFYA, NFYB

Bioinformatic
priority

High/medium

Medium
0.00519

Medium
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TA B L E 3

BRCA2 prioritized variants

Gene

hg19 Position
(Chr13)

Variant
namea

rsID

Global MAF
in dbSNP

BRCA2

g.32889437G>A

c.-407G>A

rs36221751

0.0018

BRCA2

g.32889449C>T

c.-395C>T

Novel

BRCA2

g.32889548C>T

c.-296C>T

rs563971900

BRCA2

g.32889564delG

c.-280del

Novel

BRCA2

g.32889576C>G

c.-268C>G

Novel

High/medium

BRCA2

g.32889626G>A

c.-218G>A

Novel

Medium

BRCA2

g.32889644C>T

c.-200C>T

Novel

BRCA2

g.32889647A>C

c.-197A>C

rs370721506

NA

BRCA2

g.32889669C>T

c.-175C>T

rs55880202

0.0058

BRCA2

g.32889711T>G

c.-133T>G

Novel

BRCA2

g.32889757T>G

c.-87T>G

Novel

Medium/low

BRCA2

g.32889762G>C

c.-82G>C

Novel

Medium/low

TF motif (ENCODE)b

Bioinformatic
priority
Medium
Medium

0.0004

PAX5

High/medium

ELF1, GABPA, ELK1,4

High

MAZ

Medium

MAZ

Medium
Medium
Medium

NA, no data available, TF, transcription factors.
a
Based on NM_000059.3.
b
Overlap with TF motif in ENCODE TF-ChIP datasets from all cells.

did not compete any bands showing that the bands seen in the EMSA

population frequency and/or clinical data (Supporting Information

were specific.

Tables S5 and S6). In this context, the term pathogenicity refers to a

Analysis of the regions of the BRCA2 promoter using EMSA revealed

variant that confers a high risk of disease. Importantly, these classifica-

that region containing the BRCA2:c.-296C>T variant bound nuclear

tion guidelines do not identify those variants that confer a moderate or

proteins from MCF7 nuclear extracts and that this interaction was dra-

low risk of disease.

matically reduced by introduction of the variant sequence (Figure 6a).

Of those variants identified in cases only, 26/70 (37%) of BRCA1

Competition experiments showed that these interactions were specific

variants had been reported in dbSNP at study initiation (maximum

and not competed by a nonspecific probe from an unrelated region of

global frequency = 0.006; Supporting Information Table S2), and 22/54

the BRCA1 promoter (Figure 6a).

(41%) of BRCA2 variants observed in cases only were identified in

To determine the effect of these variants on the binding of specific

dbSNP (maximum global frequency = 0.006; Supporting Information

TFs, competition and supershift analyses were performed. BRCA1:c.-

Table S3). Review of variant frequency in public reference groups iden-

287C>T overlaps with the consensus binding motif for CCAAT Box

tified 21 variants that were classifiable, as Not Pathogenic, based on

binding factors, NFYA and NFYB (Table 2 and Supporting Information

frequency in control groups (Supporting Information Table S5): six

Figure S1a), and IT analysis predicts that the variant disrupts binding

BRCA1 and five BRCA2 variants were observed at >1% frequency

of these TFs (Table 4). Consistent with these predictions, supershift

in population subgroups (stand-alone evidence against pathogenicity,

experiments show that BRCA1:c.-287C>T disrupts binding of NFYA

when detected in a nonfounder outbred population group); six BRCA1

to this region (Figure. 5d). In addition, we analyzed BRCA2:c.-296C>T,

and four BRCA2 variants occurred at frequency 0.001–0.01 (range

which maps within the consensus binding motif for PAX5 (Table 2 and

0.0014–0.0076) in at least five individuals in the reference set, which

Supporting Information Figure S1b), and is predicted by IT analysis to

combined with a low assumed prior is considered sufficient as evi-

disrupt binding of PAX5 (Table 4), by cross-competition experiments

dence against pathogenicity (Supporting Information Table S5). Fre-

using known PAX5 binding sites from hCD19 (Kozmik, Wang, Dorfler,

quency data from controls screened for this study also supported the

Adams, & Busslinger, 1992) and hDAO (Tran et al., 2015) genes. These

frequency-based classifications for eight of these 21 variants (Support-

experiments show that known PAX5 binding sites compete efficiently

ing Information Table S5).

for binding of nuclear proteins to the BRCA2 promoter region, indicat-

Segregation analysis for seven informative families aided classifi-

ing that PAX5 binding is reduced as a consequence of the nucleotide

cation for six variants, whereas histopathology likelihood ratios (LRs)

sequence change (Figure. 6b). In contrast, supershift experiments for

derived for 24 tumors altered classification for 10 variants (Supporting

POU2F2 (Oct-2) showed no evidence for BRCA1:c.-315del causing a

Information Table S6). Combining findings from qualitative and quanti-

change in binding of POU2F2 in the cell line used (data not shown).

tative methods, most variants (113/141; 80%) remained Class 3 Uncertain, largely due to a lack of data.
A total of 27/141 (19%) variants were classified as Not Pathogenic

3.5 Clinical classification of BRCA1 and BRCA2 5′
noncoding sequence variants

or Likely Not Pathogenic. Of the 21 variants prioritized for functional

Variants were classified according to the ENIGMA guidelines, which

Likely Not Pathogenic based on frequency information and/or multi-

are calibrated for classification of variants as high risk, using available

factorial analysis (Table 5), including two variants (BRCA1:c.-192T>C

analysis, eight variants (38%) were classified as Not Pathogenic or
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Variants mapping to the 5′ regions of BRCA1 and BRCA2 alter promoter activity in MCF7 and MDA-MB-468 breast cancer cells.
MCF7 (a and c) and MDA-MB-468 cells (b and d) were transfected with pGL3 vectors where luciferase expression is controlled by a portion of the
BRCA1 (B1) (a and b) or BRCA2 (B2) (c and d) promoter. Cells were transfected with plasmids containing the wild-type (WT) promoter sequence
(grey bars), positive control (B1-Ets or B2-Ets; striped bars) or the indicated variants (black bars). Luciferase expression was normalized to a
cotransfected pRL-TK plasmid. Data represent the average of three independent biological replicates ± standard deviation (SD). The horizontal
dotted line represents WT promoter activity set at 1.0-fold. The vertical dotted lines demarcate individual experiments that include WT, positive
control, and variant containing plasmids. (* P ˂ 0.05; ** P ˂ 0.01, *** P ˂ 0.005, **** P ˂ 0.0001)
FIGURE 3

and BRCA2:c.-296 C > T) that were shown to decrease promoter activ-

potential to modulate gene expression (Stranger et al., 2005; Stranger

ity and in the case of BRCA2:c.-296 C>T also resulted in perturbed TF

et al., 2007) and impact on relative disease risk, possibly in collab-

binding. Taken together this analysis indicates that none of the variants

oration with multiple other low-, moderate-, and high-risk variants

shown to affect function in this study are associated with a high risk of

(Manolio et al., 2009). This extends and validates our previous study

disease. This analysis is silent, however, on whether these variants may

(Santana dos Santos et al., 2017) by using a larger number patients

confer a moderate or low risk of disease.

analyzed over nine geographical locations, identifying additional
BC-associated variants, and showing that a subset of these variants
modulate binding of specific TFs. Further, we have compared results

4

DISCUSSION

from our bioinformatics and functional analysis to variant classifications based on ENIGMA BRCA1/2 guidelines for high-risk variation in

Next generation sequencing and gene panel testing enable rapid anal-

these genes.

ysis of gene regions that have previously not been included in standard

Through targeted sequencing of over 6,000 early onset/familial BC

screening procedures, including promoters, UTRs, introns, and extra-

patients, we identified 141 single nucleotide variants and small indels

genic regions. It is hypothesized that variants in these regions have

mapping to the 5′ noncoding regions of BRCA1 and BRCA2. Of these,
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Information theory analysis of prioritized BRCA1/2 variants

Variant name

TF motif (ENCODE)

Consequences

BRCA1:c.-408T>A

CEBPB

CEBPB site weakened (did not meet stringent filtering thresholds)

BRCA1:c.-380G>A

RXRA

Weak RXRA and IRF3 sites weakened, HNF4G site weakened.

BRCA1:c.-378C>A

RXRA

RXR unchanged, HSF1 site lost and GR site created

BRCA1:c.-315del

ATF1,2,3, CREB1a

TCF7L2 site lost and POU2F2 created

BRCA1:c.-287C>T

NFYA, NFYB

NFYA and NFYB sites lost, weak PBX3 site created
Altered TF strength did not fulfill stringent filtering thresholdsb

BRCA1:c.-273G>A
BRCA1:c.-264T>G

BHLHE32 and MYC sites created.

BRCA1:c.-220C>A

Altered TF strength did not fulfill stringent filtering thresholdsb

BRCA1:c.-192T>C

ETS1 site created, weak RFX5 site strengthened.

BRCA2:c.-407G>A

Weak MEF2A site strengthened, GATA2 site lost.

BRCA2:c.-395C>T

TEAD4 site lost.

BRCA2:c.-296C>T

PAX5

PAX5 site weakened.

BRCA2:c.-280del

ELF1, GABPA, ELK1,4

GABPA site unchanged, MXI1 andTCF3 sites lost.
Altered TF strength did not meet filtering thresholdsb

BRCA2:c.-268C>G

Altered TF strength did not meet filtering thresholdsb

BRCA2:c.-218G>A
c

BRCA2:c.-200C>T

MAZ

BRCA2:c.-197A>C

MAZc

KLF1 site abolished.
SP4 weakened, GR site weakened, TCF3 site created

BRCA2:c.-175C>T

Altered TF strength did not fulfill stringent filtering thresholdsb

BRCA2:c.-133T>G

Altered TF strength did not fulfill stringent filtering thresholdsb

BRCA2:c.-87T>G

Altered TF strength did not fulfill stringent filtering thresholdsb

BRCA2:c.-82G>C

Altered TF strength did not fulfill stringent filtering thresholdsb

a Variant overlaps this motif, but the deletion does not alter the motif sequence.
b
c

Change in information did not fulfill stringent filtering criteria, where [A] site Ri < Rsequence –1 standard deviation of TF model, or [B] where ΔRi < 4 bits.
No MAZ binding model available.

associated with BC risk (Michailidou et al., 2017), including a variant in
the TERT promoter, which creates a new binding site for Ets factors and
results in a 1.2–1.5-fold increase in luciferase activity in a promoter
reporter assay (Horn et al., 2013), and variants in the promoters of
KLHDC7A and PIDD1 (Michailidou et al., 2017). Although this supports
the hypothesis that moderate change in promoter activity can be
associated with disease risk, further work is needed to confirm this.
One of the four variants significantly altered luciferase activity
in both tested cell lines, whereas the remaining three variants only
affected luciferase activity in MCF7 cells. This may reflect the differential availability of crucial TFs in MDA-MB-468 cells (Kao et al., 2009)
and highlights the importance of undertaking that assays for functional
activity of variants in more than one cell line. Three variants, BRCA1:c.Variants in the 5′ regions of BRCA1 alter DNA:protein
complex formation. Electrophoretic mobility shift assay (EMSA)
reactions were performed with 3′ biotinylated double-stranded DNA
probes from the BRCA1 5′ region and nuclear extracts (NE) from (a)
MCF7 or (b) MDA-MB-468 cells. DNA probes contained either
wild-type (WT) or variant (Var) sequences. Free unbound probe (FP)
and probe bound by nuclear proteins (BP) are indicated
FIGURE 4

380G>A, BRCA2:c.-296C>T, and BRCA2:c.-218G>A, were also analyzed in our earlier paper (Santana dos Santos et al., 2017). Although
the cell lines used in the two studies were different (MDA-MB-231 in
Santana dos Santos et al., 2017 and MCF7 and MDA-MB-468 here),
the trends are the same in five out of six analyses. The difference for
BRCA2:c.-296C>T, which causes a significant decrease in MDA-MB231 and MCF7 cells, but not MDA-MB-468 cells, may again be indicative of differential gene expression in BC cell lines (Kao et al., 2009).

four (BRCA1:c.-315del, BRCA1:c.-287C>T, BRCA1:c.-192T>C, and

Overall, however, the consistency of results performed in two separate

BRCA2:c.-296C>T) caused a significant change in promoter activity.

laboratories underscores the robustness of the assay system.

The observed alterations in BRCA1 and BRCA2 promoter activity

Some variants were associated with a decrease in promoter activ-

are of a similar magnitude to that seen with other germline variants

ity, whereas others were associated with an increase. As TFs can

g.32889762G>C

BRCA2

BRCA2

c.-408T>A

c.-82G>C

c.-87T>G

c.-133T>G

c.-175C>T

c.-197A>C

c.-200C>T

c.-218G>A

c.-268C>G

c.-280del

c.-296C>T

c.-395C>T

c.-407G>A

c.-192T>C

c.-220C>A

c.-264T>G

c.-273G>A

c.-287C>T

c.-315del

c.-378C>A

c.-380G>A

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

Decrease

No effect

No effect

Decrease

No effect

No effect

No effect

Increase

Decrease

No effect

No effect

No effect

Luciferase
result

0.0080 (Prague,
this study)

Not pathogenicb

0.0197 (African,
FLOSSIES)

Not pathogenica

Uncertain

Uncertain

Uncertain

0.02

0.0014 (African,
FLOSSIES)

Not pathogenicb

0.02

0.02

0.02

0.02

0.02

0.02

0.02

Likely not pathogenic

Likely not pathogenic

Uncertain

0.02

0.02

Not pathogenicb
Uncertain

0.02

Uncertain
0.0080 (Prague,
this study)

0.02

0.0159 (African,
1,000 Genomes)

Not pathogenica
0.02

0.02

Uncertain

0.02

0.02

Uncertain

0.02

0.02

0.02

0.02

0.02

Prior
probability of
pathogenicity

Uncertain
0.0159 (African,
1,000 Genomes)

0.0015 (African,
1,000 Genomes)

Highest MAF
(population,
database)

Not pathogenica

Uncertain

Uncertain

Uncertain

Uncertain

Combined
interpretation of
frequency data &
multifactorial
analysis

0.52 (1)

3.07 (1)

Segregation
Bayes score
(# families)

1.08 (1)

0.37 (1)

0.72 (1)

0.69 (1)

1.91 (8)

0.55 (6)

0.51 (1)

0.64 (1)

1.67 (1)

Tumor
histopathology
likelihood ratio
(# tumors)

1.08

0.37

0.38

0.69

5.87

0.55

0.51

0.64

1.67

Combined
odds for
causality

NA

0.0075

0.0076

NA

0.1069

NA

NA

NA

NA

Posterior
probability of
pathogenicityc

NA, not applicable: multifactorial classification not assigned as the combined odds of causality were insufficient (≥0.5 and ≤2) to derive a posterior probability of pathogenicity (Vallee et al., 2016).
a Not pathogenic based on frequency > 1% in an outbred sampleset.
b
Variant allele assigned a low prior probability of pathogenicity of 0.02 assuming conservatively that 2/100 of such variants might be associated with a high risk of cancer and allele frequency ≥0.001 and < 0.01 in
outbred sample set.
c
Posterior probabilities used to assign IARC 5-tier class as described in Plon et al., 2008.

g.32889711T>G

g.32889757T>G

BRCA2

g.32889669C>T

BRCA2

BRCA2

g.32889576C>G

BRCA2

g.32889647A>C

g.32889564delG

BRCA2

BRCA2

g.32889548C>T

BRCA2

g.32889626G>A

g.32889449C>T

BRCA2

g.32889644C>T

g.32889437G>A

BRCA1

BRCA2

g.41277460A>G

BRCA1

BRCA2

g.41277532A>C

g.41277488G>T

BRCA1

g.41277555G>A

BRCA1

g.41277541C>T

g.41277583del

BRCA1

BRCA1

g.41277646G>T

BRCA1

BRCA1

g.41277676A>T

g.41277648C>T

BRCA1

Gene

HGVS c.
nomenclature

Classification of prioritized variants

Genomic
location (hg19)
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F I G U R E 5 Variant sequences in the BRCA1 5′ region alter specific DNA:protein complex formation. Competition electrophoretic mobility shift
assay (EMSAs) were performed using 3′ biotinylated double-stranded DNA probes containing sequences from the BRCA1 5′ region surrounding
the B1:c.-315del (a and b) and B1:c.-287C>T (c) variants. DNA probes containing the wild-type (WT) or variant (Var) sequence were incubated
with nuclear extracts from MCF7 cells (MCF7 NE) or MDA-MB 468 cells (468 NE) in the presence (+) or absence (–) of unlabeled WT, Var, or
nonspecific (NS) competitor (Comp) DNA. Free unbound probe (FP) and specific DNA:protein complexes (arrowheads) are indicated. Supershift
experiments (d) were performed with the BRCA1:c.-287C (WT) probe and antibodies to NFYA, Oct-2 (POU2F2) and PAX5. The supershifted NFYA
complex is indicated by asterisk (*)

Variants in the 5′ region of BRCA2 alter specific DNA:protein complex formation. Competition electrophoretic mobility shift assay
(EMSAs; a) were performed using 3′ biotinylated double-stranded (ds) DNA probes containing sequences from the BRCA2 5′ region surrounding
the BRCA2:c.-296C>T variant. DNA probes containing the wild-type (WT) or variant (Var) sequence were incubated with nuclear extracts from
MCF7 cells (MCF7 NE) in the presence (+) or absence (–) of unlabeled WT, Var, or nonspecific (NS) competitor (Comp) DNA. Cross-competition
EMSAs (b) contained BRCA2 WT sequences and increasing concentrations of ds competitor DNA containing unlabeled WT, Var, or PAX5 binding
sites from the hCD19 gene and D-amino acid oxidase gene (hDAO). Free unbound probe (FP) and specific DNA:protein complexes (arrowheads)
are indicated
FIGURE 6
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function as activators or repressors, a variant-associated change in

neighboring sequences (Zhu et al., 2012) indicating possible mecha-

TF binding can result in either a decrease or an increase in promoter

nisms for divergent activities of NFY proteins at this site.

(or other regulatory element) activity. Differences in the quanta and

BRCA1:c.-192T>C, which lies in the 5′ UTR, decreased reporter

direction of promoter activity have been reported previously (e.g.,

activity but did not bind any proteins from MCF7 nuclear extracts in

Fraile-Bethencourt et al., 2018; Santana dos Santos et al., 2017) and

EMSA analysis. Possibly, EMSA binding conditions are not optimal for

have also been shown to differ between cell lines potentially reflecting

binding of factors to this sequence or alternatively, this reduction in

the availability of TFs or cofactors (e.g., Zn).

promoter activity could be by posttranscriptional mechanisms as seen

Three of the variants, BRCA1:c.-315del, BRCA1: c.-287C>T, and

for BRCA2:c.-26G>A (Gochhait et al., 2007).

BRCA2:c.-296C>T, altered protein binding. ENCODE ChIP-seq data

Using existing prediction models developed for high risk variants,

from BC cell lines indicate candidate proteins that are bound to the

population frequency and clinical information classified 27 variants

genomic regions containing these variants (Figure 2 and Supporting

as "Not Pathogenic" or "likely Not Pathogenic." This included two

Information Figure S1). These include E2F1, CEBPB, GATA3, Max,

BRCA1 and six BRCA2 variants with functional assay data available,

ELF1, GABP, and FOXA1 for BRCA1 and E2F1, MYC, ELF1, GABP, Max,

six with no statistically significant effect on promoter activity, and

and PML for BRCA2. Interestingly, a number of these factors have pre-

two that decreased promoter activity in vitro. These two variants,

viously been implicated in BC.

BRCA1:c.-192T>C and BRCA2:c.-296C>T, were observed in popu-

In addition, ENCODE ChIP-seq data from cell lines derived from

lation subgroup controls; notably BRCA1:c.-192T>C was observed

tissues other than breast indicate that the variants that affect pro-

at a frequency of >1%, which is considered stand-alone evidence

tein binding are located within consensus motifs for specific TFs

against pathogenicity (defined as high risk of cancer) for BRCA1/2

associated with these regions (Tables 2 and 3; Supporting Informa-

variation. This suggests that promoter region variants, irrespective of

tion Figure S1). BRCA1:c.-287C>T overlaps with the consensus bind-

bioinformatic prediction or functional assay results, are unlikely to be

ing motif for CCAAT Box binding factors, BRCA1:c.-315del is located

associated with a high risk of cancer. This is consistent with current

in a consensus motif for CREB/ATF proteins, although the deletion

evidence from ENIGMA studies (de la Hoya et al., 2016), which suggest

does not modify this motif, and BRCA2:c.-296C>T is located within

that an allele resulting in only ∼20–30% expression of BRCA1 tran-

the consensus motif for PAX5. IT analysis also predicts that all these

script/s encoding functional transcripts is not associated with high risk

variants alter TF binding (Table 4 and Supporting Information Table

of BC. The low impact of these variants on risk is likely to reflect the

S4). We show that BRCA1:c.-287C>T disrupts the binding of NFYA

complex interplay of TFs and DNA elements, and possible redundancy

to the BRCA1 promoter region. Furthermore, we present evidence

in the system. For example, a variant in one TF binding site within a

that BRCA2:c.-296C>T disrupts the binding of PAX5. BRCA1:c.-315del

cluster may be buffered by other binding sites and thus insufficient on

lies in the so-called positive regulator region that has been shown

its own to reduce gene expression markedly (Lu & Rogan, 2018).

to bind GABP𝛼, CREB, and AP-1 proteins (Atlas et al., 2000; Atlas,

Given that moderate- and low-risk variants often occur in >1% of

Stramwasser, & Mueller, 2001; Graves, Zhou, MacDonald, Mueller,

the population, and that the remaining 13 variants had insufficient evi-

& Roskelley, 2007; Suen & Goss, 1999; Thakur & Croce, 1999).

dence available to assess clinical significance, we cannot exclude the

Although these proteins are generally considered activators of tran-

possibility that BRCA1/2 promoter region variants, in particular those

scription, repression of promoter activity by BRCA1:c.-315del sug-

with proven functional effect, may be associated with a moderate or

gests the recruitment of an additional transcriptional repressor or

low risk of cancer. This indicates an urgent need to further develop

corepressor to this region. IT analysis predicts creation of a bind-

prediction models to accommodate criteria for moderate- or low-

ing site for POU2F2, a known repressor; however, we found no evi-

risk variants by extending the BRCA1/2-specific criteria developed by

dence to suggest that this variant increased POU2F2 binding in the

ENIGMA (https://www.enigmaconsortium.org/), or even the generic

cell line used, although it is possible that changes may be observ-

variant classification criteria developed by the American College of

able in other cell lines. Biochemical studies, including mass spectrom-

Medical Genetics for Mendelian disorders (Richards et al., 2015).

etry, will be required to validate and discover other alterations in TF
binding.

This study has evaluated the significance of single nucleotide
variants and small indels mapping to the 5′ noncoding region of BRCA1

One variant, BRCA1:c.-287C>T, increased promoter activity and

and BRCA2 using bioinformatic, biological, and biochemical analyses in

decreased protein:DNA interactions. This increase in promoter activ-

combination with consideration of clinical data that inform qualitative

ity was unanticipated because this variant is within a consensus motif

and quantitative variant classification. We present data to suggest that

for the CCAAT box binding proteins, NFYA and NFYB, and muta-

a subset of these variants have functional effects on gene regulation.

tion of this CCAAT box has previously been shown to reduce BRCA1

We also present evidence that variants mapping to and affecting the

promoter activity in MCF7 cells (Bindra et al., 2005; Xu, Cham-

function of BRCA promoters are not likely to be associated with a high

bers, & Solomon, 1997). This variant also decreases promoter activ-

risk of cancer. We propose that studies of differing design, such as

ity in MDA-MB-231 cells (Santana dos Santos et al., 2017). Here,

very large-scale case-control sequencing studies able to detect rare

we show that the BRCA1:c.-287C>T variant reduces NFYA binding.

variation, will be required to address if a low to moderate risk of cancer

Importantly, NFY proteins can function as transcriptional activators or

may be associated with BRCA1/2 regulatory region variation that has

repressors depending on recruitment of corepressors or coactivators

not been captured to date by genome-wide association genotyping

(Peng & Jahroudi, 2002; Peng et al., 2007) and recruitment of TFs to

platforms. We believe that the bioinformatic and functional analysis
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presented will be important to define the design and interpretation
of such future sequencing studies. We also believe that this study
highlights the challenges associated with classifying variants with
respect to low or moderate disease risk, and the need to be cautious in
the clinical use of information on individual variants that is likely to be
one of many factors contributing to disease risk.
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